Pricing Log in Create free account

Avalo Therapeutics, Inc. (AVTX) vs Nuvectis Pharma, Inc. (NVCT)

Avalo Therapeutics, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Avalo Therapeutics, Inc. and Nuvectis Pharma, Inc. are of similar size ($644.1M and $618.0M). Across the 9 metrics below, Nuvectis Pharma, Inc. leads on 5 and Avalo Therapeutics, Inc. on 4.

Valuation

Metric AVTX NVCT Biotechnology median
P/E n/m n/m 8.50
P/S 394.06 n/m 9.71
P/B 1.10 47.77 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 82.27 n/m 9.21
Earnings yield (38.78%) (7.09%) (33.15%)
Free cash flow yield (28.32%) (4.50%) (25.50%)

Profitability

Metric AVTX NVCT Biotechnology median
Gross margin 64.72% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (36.27%) (233.30%) (56.36%)
Return on assets (32.50%) (122.61%) (48.04%)
Return on invested capital (118.21%) 0.00% 0.00%

Growth

Metric AVTX NVCT Biotechnology median
Revenue growth (TTM) (92.65%) — 6.02%
EPS growth (last fiscal year) (24.62%) (18.92%) 30.26%
Revenue growth, 5-year CAGR (61.19%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AVTX NVCT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 19.31 1.68 4.72
Net debt to EBITDA 1.36 1.15 0.96

Dividend

Metric AVTX NVCT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AVTX NVCT Biotechnology median
Market cap 644.10m 617.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack